Abstract |
Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe with attractive clinical responses. Re-challenge 177Lu-PSMA therapy in early responders has been shown to be safe and effective. We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m2 weekly × 6 weeks) as a radiosensitizer with re-challenge 177Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of 177Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge 177Lu-PSMA therapy and low-dose docetaxel (Taxol-177Lu-PSMA) with no recorded tumour resistance.
|
Authors | Masha Maharaj, Lucille Heslop, Trisha Govender, Nisaar Korowlay, Aviral Singh, Partha Choudhary, Mike Sathekge |
Journal | Nuclear medicine and molecular imaging
(Nucl Med Mol Imaging)
Vol. 55
Issue 3
Pg. 136-140
(Jun 2021)
ISSN: 1869-3474 [Print] Germany |
PMID | 34093893
(Publication Type: Case Reports)
|
Copyright | © Korean Society of Nuclear Medicine 2021. |